An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for ...

Immune cells, pictured here in bright teal, occupy the epithelial layers between the skin surface and its stem cells and act ...

Researchers developed an in vitro micronucleus test using human induced pluripotent stem cell-derived T lymphocytes, which ...

Epidermal stem cells oversee the skin’s ability to respond to stressors from the outside world and then return to a steady ...

Organoid and clinical single-cell data link a DHX58-positive, CD62L-positive stem-like T-cell state to immune checkpoint ...

Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported ResultsIOV-LUN-202 Cohorts 1 and ...

Mexico's health regulator authorized the country's first clinical trial using domestically manufactured CAR-T cells, allowing ...

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven ...

When treatment is urgent, are there clues to foresee the outcome?When you are told of a relapse and must start the next treatment as soon as possible, the first thing many people want to know is, ...

National Institutes of Health (NIH) released the following:  Early results of the first clinical trial to evaluate the drug ...

Shanghai Junshi Biosciences Co., Ltd. announced that the first patient dosing has been completed in a randomized, open-label, multicenter phase 3 clinical study of the company?s product, a recombinant ...

Early results of the first clinical trial (link is external) to evaluate the drug invikafusp alfa (invika) in humans indicate that the pioneering ...